Precision BioSciences reports Q1 EPS ($2.21), consensus ($2.42)

Reports Q1 revenue $29,000, consensus $5M. “We started 2025 with strong momentum and a focus on generating impactful clinical data across our in vivo gene editing pipeline. Early this year, data from the OTC-HOPE trial provided the first clinical validation for ARCUS in vivo gene insertion following a complete response in an infant with OTC-deficiency,” said Michael Amoroso, CEO of Precision BioSciences (DTIL). “In addition, the Phase 1 ELIMINATE-B trial evaluating PBGENE-HBV, our lead program for chronic Hepatitis B, is progressing as planned. We presented encouraging data at the recent EASL Congress highlighting the safety of PBGENE-HBV after repeat dosing as planned in the ELIMINATE-B protocol. We look forward to sharing additional updates from the ELIMINATE-B trial throughout 2025, including antiviral efficacy data from each cohort upon completion of three dose administrations. In addition, we recently received U.S. investigational new drug approval to expand this important global trial as well as Fast Track Designation from the U.S. Food and Drug Administration underscoring ARCUS’ potential to deliver a curative treatment option for people in need living with chronic Hepatitis B.”